Development of a Novel Prognostication Model for Patients With Metastatic RCC Receiving First-Line Molecularly Targeted Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Development of Novel ACN (Albumin, C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio) Prognostication Model for Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Molecular-Targeted Therapy
Urol. Oncol 2020 Sep 18;[EPub Ahead of Print], K Tamura, R Ando, K Takahara, T Ito, K Kanao, T Yasui, R Shiroki, H MiyakeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.